GROWTH OPPORTUNITIES IN PREDICTIVE GENETIC DIAGNOSTICS, AI ENABLED DRUG DISCOVERY, AND DIAGNOSTICS PLATFORMS

GROWTH OPPORTUNITIES IN PREDICTIVE GENETIC DIAGNOSTICS, AI ENABLED DRUG DISCOVERY, AND DIAGNOSTICS PLATFORMS

RELEASE DATE
21-Jan-2022
REGION
Global
Research Code: D759-00-28-00-00
SKU: HC03491-GL-TA_26195
$950.00
In stock
SKU
HC03491-GL-TA_26195
$950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on innovations that leverage artificial intelligence (AI) and machine learning (ML) algorithms for diagnostics and drug discovery applications. Innovations around AI and ML augmented diagnostics have been highlighted, which include molecular diagnostics, both PoC immunoassays, image-based diagnostics and molecular diagnostics. In particular, technologies, which enable early diagnosis of cancers, support biomarker discovery and disease prognosis have been covered. Another focus of this issue is on predictive genetic tests, which offer a comprehensive picture of an individual’s risk of disease development. Many of the innovations covered in this issue support biomarker discovery and novel therapeutics development. Microbiome diagnostics and innovation around a biocompatible integrated regenerative medicine platform are some of the other interesting innovations captured in this issue.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Single cell analysis, AI-based diagnostics, generative chemistry, AI drug discovery, predictive genetics, breast cancer screening, colorectal screening, regenerative medicine, medical device, AI genomic tests, variant detection, next gen sequencing, automated library preparation, whole genome sequencing, DNA arrays, cell therapy, immunoprotection, liquid biopsy, microbiome testing, movement disorders, neurodegenerative disease, PCR, molecular diagnostics, immunoassay, conformal coating, stem cells, diabetes, cancer, type1 diabetes, hemophilia

Table of Contents

INNOVATIONS IN LIFE SCIENCES, HEALTH & WELLNESS

  • MULTIOMICS LIQUID BIOPSY DRIVING EARLY CANCER DETECTION
  • MULTIMODAL TEST IDENTIFIES NEW BIOMARKERS
  • FREENOME—INVESTOR DASHBOARD
  • POC MICROFLUIDIC IMMUNOFLUORESCENCE ASSAY IMPROVES DIAGNOSTIC ACCURACY OF SARS-COV-2
  • RAPID MICROFLUIDIC IMMUNOFLUROSCENCE ASSAY
  • LUMIRADX—DASHBOARD
  • AI-POWERED MEDICINAL CHEMISTRY PLATFORM ACCELERATING DRUG DISCOVERY
  • INTEGRATING GENERATIVE CHEMISTRY AND SYNTHESIS TECHNOLOGIES
  • POSTERA—INVESTOR DASHBOARD
  • AI DRIVEN DRUG DISCOVERY PLATFORM FOR CELLULAR AGING
  • UTILIZING AI PLATFORM TO IDENTIFY NEW COMPOUNDS FOR REVERSING CELLULAR AGING
  • FOUNTAIN THERAPEUTICS—INVESTOR DASHBOARD
  • INTEGRATED DRUG DEVELOPMENT PLATFORM FOR DEGENERATIVE MOVEMENT DISORDERS
  • ML-BASED CELL PROFILING PALTFORM FOR DRUG DISCOVERY
  • NINE SQUARE THERAPEUTICS INC.—INVESTOR DASHBOARD
  • DNA-BASED WELLNESS TEST EVALUATING DISEASE RISK
  • TECHNOLOGY FOR ANALYZING MULTIPLE MARKER GENES
  • MAPMYGENOME—INVESTOR DASHBOARD
  • WHOLE-GENOME SEQUENCING FOR EVALUATING DISEASE RISK
  • TECHNOLOGY TO EVALUATE MULTIPLE MEDICALLY ACTIONABLE GENES
  • VERITAS GENETICS—INVESTOR DASHBOARD
  • PERSONALIZED MICROBIOME AND GENETIC TESTING
  • GENETIC TEST FOR DETECTING MUTATIONS
  • BIONE VENTURES PRIVATE LIMITED—INVESTOR DASHBOARD
  • ORAL SMALL MOLECULE INHIBITOR
  • ALTERNATIVE TREATMENT TO CHEMOTHERAPY
  • CLOVIS ONCOLOGY—INVESTOR LENS
  • DISEASE-RISK TESTING FOR HEREDITARY CANCER
  • GENETIC TESTING FOR ANALYZING HEREDITARY HEART DISEASES
  • COLOR HEALTH—INVESTOR DASHBOARD
  • INTEGRATED PROGNOSTIC FOR PERSONALIZED BREAST CANCER TREATMENT
  • TECHNOLOGY FOR DIAGNOSING HEALTH RISKS
  • PRELUDE CORPORATION—INVESTOR LENS
  • INTEGRATED, SCALABLE SINGLE ANALYSIS PLATFORM
  • HIGH-THROUGHPUT SINGLE-CELL ANALYSIS TECHNOLOGY
  • 10X GENOMICS—INVESTOR DASHBOARD
  • MIRAM® KIT FOR GLUCOSAMINOGLYCAN-BASED EARLY CANCER DETECTION
  • ELYPTA PIONEERS THE GAG-BASED MOLECULAR DIAGNOSTIC TECHNOLOGY FOR VARIOUS TYPES OF CANCERS
  • ELYPTA AB–INVESTOR DASHBOARD
  • MOLECULAR COUNTER -DNA TEST FOR MULTIPLE DIAGNOSTIC APPLICATIONS
  • BILLIONTOONE’S TECHNOLOGY INCREASES DIAGNOSTIC RESOLUTION 1,000-FOLD
  • BILLIONTOONE–INVESTOR DASHBOARD
  • ARTIFICIAL INTELLIGENCE-BASED ALGORITHM FOR DETECTING INFECTIONS
  • PCR.AI IS A COST-EFFECTIVE, ACCURATE, AND VERSATILE PLATFORM TO DIAGNOSE MANY DISEASES
  • DIAGNOSTICS.AI–INVESTOR DASHBOARD
  • INTEGRATED , BIOCOMPATIBLE REGENERATIVE MEDICINE PLATFORM TARGETING CHRONIC DISEASES
  • SERNOVA’S REGENERATIVE MEDICINE PLATFORM MAINTAINS CELLS VIABILITY AND FUNCTIONALITY
  • SERNOVA–INVESTOR DASHBOARD
  • GENETICALLY MODIFIED ENUCLEATED MESENCHYMAL STROMAL CELLS FOR TARGETED DRUG DELIVERY
  • UNIVERSITY OF CALIFORNIA’S TECHNOLOGY VALUE PROPOSITION
  • LOCALIZED ANTI-CANCER DRUG SYNTHESIS ENHANCES ANTITUMOR ACTIVITY
  • RIKEN’S TECHNOLOGY VALUE PROPOSITION
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • LEGAL DISCLAIMER
Related Research
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on innovations that leverage artificial intelligence (AI) and machine learning (ML) algorithms for diagnostics and drug discovery applications. Innovations around AI and ML augmented diagnostics have been highlighted, which include molecular diagnostics, both PoC immunoassays, image-based diagnostics and molecular diagnostics. In particular, technologies, which enable early diagnosis of cancers, support biomarker discovery and disease prognosis have been covered. Another focus of this issue is on predictive genetic tests, which offer a comprehensive picture of an individual’s risk of disease development. Many of the innovations covered in this issue support biomarker discovery and novel therapeutics development. Microbiome diagnostics and innovation around a biocompatible integrated regenerative medicine platform are some of the other interesting innovations captured in this issue. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Single cell analysis, AI-based diagnostics, generative chemistry, AI drug discovery, predictive genetics, breast cancer screening, colorectal screening, regenerative medicine, medical device, AI genomic tests, variant detection, next gen sequencing, automated library preparation, whole genome sequencing, DNA arrays, cell therapy, immunoprotection, liquid biopsy, microbiome testing, movement disorders, neurodegenerative disease, PCR, molecular diagnostics, immunoassay, conformal coating, stem cells, diabetes, cancer, type1 diabetes, hemophilia
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-28-00-00
Is Prebook No
Ti Codes D759